Fusion protein holds promise for treating pulmonary arterial hypertension

(Brigham and Women's Hospital) In a paper published in Science Translational Medicine, researchers illuminate the underlying biological pathways that may lead to vessel destruction in pulmonary arterial hypertension. Their results provide a biological explanation for why proteins called activins and growth and differentiation factors (GDFs) might contribute to pulmonary vascular disease, and provide an explanation of how the activin/GDF-blocking drug sotatercept, currently in clinical trials, ma...